Basal insulin for the management of diabetic ketoacidosis

Published:August 30, 2017DOI:


      • Basal insulin with regular insulin hastens ketoacidosis resolution and prevents hyperglycemia.
      • Basal insulin with regular insulin infusion was well tolerated.
      • This could potentially lead to a shorter ICU length of stay and reduced costs in the treatment of DKA.


      Due to its pharmacokinetic properties, it has been suggested that long-acting insulin analogues may have a role in facilitating the transition from continuous intravenous insulin infusion to subcutaneous maintenance therapy in patients with DKA for prevention of rebound hyperglycemia, particularly if there are high insulin requirements. Concomitant administration of basal insulin analogues with regular insulin infusion accelerates ketoacidosis resolution and prevents rebound hyperglycemia.
      Several studies have investigated the use of basal insulin in the management of DKA. Studies have been instituted on pediatric patients and adult patients.
      These studies reveal that co-administration of basal insulin in combination with an insulin infusion in the acute management of DKA is feasible.
      Basal insulin co-administration with regular insulin infusion was well tolerated, associated with faster resolution of acidosis without any adverse effects; patients required a shorter duration of intravenous insulin infusion and had a lower total dose of intravenous insulin and significantly decreased hyperglycemia after discontinuation of the intravenous insulin. This could potentially lead to a shorter ICU length of stay and reduced costs in the treatment of DKA.
      However, this approach may be associated with an increased risk of hypokalemia.
      The current literature on this management approach is incomplete, due to its many limitations (retrospective nature, small sample size, nonrandomized design).
      Additional prospective randomized studies are needed on this new therapeutic approach in the management patients with DKA.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kitabchi A.E.
        Low-dose insulin therapy in diabetic ketoacidosis: fact or fiction.
        in: DeFronzo R. Diabetes metabolism reviews. John Wiley, Sons, New York1989: 337-363
        • Kitabchi A.E.
        • Umpierrez G.E.
        • Murphy M.B.
        • et al.
        Management of hyperglycemic crises in patients with diabetes.
        Diabetes Care. 2001; 24: 131-153
        • Umpierrez G.E.
        • Kelly J.P.
        • Navarrete J.E.
        • Casals M.M.
        • Kitabchi A.E.
        Hyperglycemic crises in urban blacks.
        Arch Intern Med. 1997; 157: 669-675
        • Kitabchi A.E.
        • Umpierrez G.E.
        • Murphy M.B.
        Diabetes ketoacidosis and hyperglycemic hyperosmolar state.
        in: DeFronzo R.A. Ferrannini E. Keen H. Zimmet P. International textbook of diabetes mellitus. 3rd ed. John Wiley, Sons, Ltd, Chichester, UK2004: 1101-1119
        • McKeage K.
        • Goa K.L.
        Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
        Drugs. 2001; 61: 1599-1624
        • Dunn C.J.
        • Plosker G.L.
        • Keating G.M.
        • McKeage K.
        • Scott L.J.
        Insulin glargine: an updated review of its use in the management of diabetes mellitus.
        Drugs. 2003; 63: 1743-1778
        • Bunn S.
        • Halm M.
        Long-acting insulin on the road to recovery with diabetic ketoacidosis.
        Am J Crit Care. 2016; 25: 277-280
        • Cardoso L.
        • Vicente N.
        • Rodrigues D.
        • Gomes L.
        • Carrilho F.
        Controversies in the management of hyperglycemic emergencies in adults with diabetes.
        Metab Clin Exp. 2017; 68: 43-54
        • Porcellati F.
        • Rosetti P.
        • Busciantella N.R.
        • et al.
        Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes.
        Diabetes Care. 2007; 30: 2447-2452
        • Lepore M.
        • Pampanelli S.
        • Fanelli C.
        • et al.
        Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
        Diabetes. 2000; 49: 2142-2148
        • Gallagher B.R.
        • Mahony O.M.
        • Rozanski E.A.
        • Buob S.
        • Freeman L.M.
        A pilot study comparing a protocol using intermittent administration of glargine and regular insulin to a continuous rate infusion of regular insulin in cats with naturally occurring diabetic ketoacidosis.
        J Vet Emerg Crit Care (San Antonio). 2015; 25: 234-239
        • Marshall R.D.
        • Rand J.S.
        • Gunew M.N.
        • Menrath V.H.
        Intramuscular glargine with or without concurrent subcutaneous administration for treatment of feline diabetic ketoacidosis.
        J Vet Emerg Crit Care (San Antonio). 2013; 23: 286-290
        • Shankar V.
        • Haque A.
        • Churchwell K.B.
        • Russell W.
        Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children.
        Intensive Care Med. 2007; 33: 1173-1178
        • Harrison V.S.
        • Rustico S.
        • Palladino A.A.
        • Ferrara C.
        • Hawkes C.P.
        Glargine co-administration with intravenous insulin in pediatric diabetic ketoacidosis is safe and facilitates transition to a subcutaneous regimen.
        Pediatr Diabetes. 2016;
        • Hsia E.
        • Seggelke S.
        • Gibbs J.
        • et al.
        Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.
        J Clin Endocrinol Metab. 2012; 97: 3132-3137
        • Doshi P.
        • Potter A.J.
        • De Los Santos D.
        • Banuelos R.
        • Darger B.F.
        • Chathampally Y.
        Prospective randomized trial of insulin glargine in acute management of diabetic ketoacidosis in the emergency department: a pilot study.
        Acad Emerg Med. 2015; 22: 657-662
        • Savage M.W.
        • Dhatariya K.K.
        • Kilvert A.
        • Joint British Diabetes Societies
        • et al.
        Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis.
        Diabet Med. 2011; 28: 508-515
        • Kitabchi A.E.
        • Umpierrez G.E.
        • Miles J.M.
        • Fisher J.N.
        Hyperglycemic crises in adult patients with diabetes.
        Diabetes Care. 2009; 32: 1335